{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Khosravifarsani M"],"pubmed_abstract":["To overcome resistance to chemotherapy for colorectal cancer, we propose to validate <i>in vivo</i> a novel terpyridine-platinum (TP) compound radiolabeled with the radio-theranostic isotope <sup>64</sup>Cu. <i>In vivo</i> stability, biodistribution, PET imaging, tumor growth delay, toxicity and dosimetry of [<sup>64</sup>Cu]NOTA-C3-TP were determined. The current experimental studies show that [<sup>64</sup>Cu]NOTA-C3-TP is stable <i>in vivo</i>, rapidly eliminated by the kidneys and has a promising tumor uptake ranging from 1.8 ± 0.4 to 3.0 ± 0.2 %ID/g over 48 h. [<sup>64</sup>Cu]NOTA-C3-TP retarded tumor growth by up to 6 ± 2.0 days and improved survival relative to vehicle and non-radioactive [<sup>Nat</sup>Cu]NOTA-C3-TP over 17 days of tumor growth observation. This effect was obtaine"],"journal":["Frontiers in medicine"],"pagination":["975213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9549809"],"repository":["biostudies-literature"],"pubmed_title":["<i>In vivo</i> behavior of [<sup>64</sup>Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer."],"pmcid":["PMC9549809"],"pubmed_authors":["Ait-Mohand S","Paquette B","Sanche L","Khosravifarsani M","Guerin B"],"additional_accession":[]},"is_claimable":false,"name":"<i>In vivo</i> behavior of [<sup>64</sup>Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer.","description":"To overcome resistance to chemotherapy for colorectal cancer, we propose to validate <i>in vivo</i> a novel terpyridine-platinum (TP) compound radiolabeled with the radio-theranostic isotope <sup>64</sup>Cu. <i>In vivo</i> stability, biodistribution, PET imaging, tumor growth delay, toxicity and dosimetry of [<sup>64</sup>Cu]NOTA-C3-TP were determined. The current experimental studies show that [<sup>64</sup>Cu]NOTA-C3-TP is stable <i>in vivo</i>, rapidly eliminated by the kidneys and has a promising tumor uptake ranging from 1.8 ± 0.4 to 3.0 ± 0.2 %ID/g over 48 h. [<sup>64</sup>Cu]NOTA-C3-TP retarded tumor growth by up to 6 ± 2.0 days and improved survival relative to vehicle and non-radioactive [<sup>Nat</sup>Cu]NOTA-C3-TP over 17 days of tumor growth observation. This effect was obtaine","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T21:41:13.435Z","creation":"2025-04-04T21:41:13.435Z"},"accession":"S-EPMC9549809","cross_references":{"pubmed":["36226156"],"doi":["10.3389/fmed.2022.975213"]}}